文献速递腹部介入CTUS

经皮影像引导腹盆腔脓肿引流时光动力疗法的安全性与可行性:1期试验

Safety and Feasibility of Photodynamic Therapy for Percutaneous Image-guided Abdominopelvic Abscess Drainage: Phase 1 Trial.
PubMed 文献 · Radiology · 2024-01-01

这项前瞻性、开放标签、剂量递增、首次人体1期临床研究纳入18例接受CT或US引导下经皮腹盆腔脓肿引流的患者,在引流后行亚甲蓝光动力疗法(MB-PDT),激光照度为20 mW/cm²,能量密度分组为6、12、18、24、30和36 J/cm²(每组n=3)。主要结局为安全性,所有18例患者均未观察到不良安全结局,未发生研究相关不良事件,操作未增加报告疼痛(P=0.1);接受较高能量密度(30和36 J/cm² vs 6 J/cm²)者临床症状和发热持续时间更短(P=0.03)。

要点

  • MB-PDT作为影像引导经皮脓肿引流的辅助手段在全部18例中安全可行,未观察到负性安全结局。
  • 未发生研究相关不良事件,操作未增加报告疼痛(P=0.1)。
  • 较高能量密度(30和36 J/cm² vs 6 J/cm²)者临床症状和发热持续时间更短(P=0.03)。

核心结论

  • MB-PDT是影像引导经皮脓肿引流的安全可行辅助手段,临床指标提示对PDT存在剂量依赖性反应。

研究设计与样本

  • 前瞻性、开放标签、剂量递增、首次人体、注册的1期临床研究,纳入2015年1月至2020年3月及2022年9月至2023年9月接受CT或US引导下经皮腹部或盆腔脓肿引流的参与者,共18例(平均年龄60.1岁±18.3[SD],10例女性)。

诊断标准与关键数值

  • 激光照度为20 mW/cm²,能量密度分组为6、12、18、24、30和36 J/cm²(每组n=3);主要结局安全性以无脂肪栓塞、亚甲蓝逃逸、脓肿壁损伤及需手术取出光纤为指标。

临床应用与阅片要点

  • 作者结论认为MB-PDT是影像引导经皮脓肿引流的安全可行辅助手段,临床指标提示剂量依赖性反应。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Background Standard-of-care abscess management includes image-guided percutaneous drainage and antibiotics; however, cure rates vary, and concern for antibiotic-resistant bacteria is growing. Photodynamic therapy (PDT), which uses light-activated dyes to generate cytotoxic reactive oxygen species, could complement the standard of care by sterilizing the abscess at the time of drainage. Purpose To evaluate safety and feasibility of PDT with methylene blue (hereafter, MB-PDT) at the time of percutaneous abscess drainage. Materials and Methods This prospective, open-label, dose-escalation, first-in-humans, registered phase 1 clinical study of MB-PDT included participants who underwent percutaneous abdominal or pelvic abscess drainage with CT or US guidance from January 2015 to March 2020 and September 2022 to September 2023. Following drainage, MB-PDT was performed with laser illumination at a fluence rate of 20 mW/cm2, with fluence groups of 6, 12, 18, 24, 30, and 36 J/cm2 (n = 3 each). The primary outcome was safety, indicated by absence of fat embolism, MB escape, abscess wall damage, and need for surgery to remove optical fibers. Preliminary efficacy end points included the time to drainage catheter removal, drainage catheter output volume, and clinical symptom and fever duration. Relationships between fluence and outcomes were analyzed with Spearman correlation and linear regression analyses, and ordinary one-way analysis of variance was used for group comparisons. Results MB-PDT was safe and feasible in all 18 participants (mean age, 60.1 years ± 18.3 [SD]; 10 female), with no negative safety outcomes observed for any participant. No study-related adverse events were encountered, and the procedure did not increase reported pain (P = .1). Clinical symptom and fever duration was shorter in participants receiving higher fluences (30 and 36 J/cm2 vs 6 J/cm2) (P = .03). The presence of antibiotic-resistant bacteria was not predictive of clinical symptom and fever duration (β = 0.13, P = .37). Conclusion MB-PDT was a safe and feasible adjunct to image-guided percutaneous abscess drainage. Clinical measures indicated a dose-dependent response to PDT. ClinicalTrials.gov registration no.: NCT02240498 © RSNA, 2024 Supplemental material is available for this article. See also the editorial by Johnston and Goldberg in this issue.

来源:Radiology,查看原文。版权归原作者所有。

引用

  1. Baran TM, Bass DA, Christensen L, et al. Safety and Feasibility of Photodynamic Therapy for Percutaneous Image-guided Abdominopelvic Abscess Drainage: Phase 1 Trial. Radiology. 2024. PMID: 38501946. doi:10.1148/radiol.232667

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。